CRP and depressive symptom measurement: To conclude, we demonstrate that CCL20 is a novel and CRP-independent marker with the potential of being diagnosis-specific for schizophrenia, and TRAIL is a transdiagnostic marker for depression and schizophrenia, while further studies on the influence of psychotropic medication are warranted to confirm this finding.